Compare JFBR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JFBR | PFSA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Israel | United States |
| Employees | 11 | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.7M |
| IPO Year | N/A | N/A |
| Metric | JFBR | PFSA |
|---|---|---|
| Price | $3.01 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.0K | ★ 6.8M |
| Earning Date | 03-31-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.05 |
| 52 Week High | $7.87 | $4.22 |
| Indicator | JFBR | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 46.38 |
| Support Level | $0.47 | $0.24 |
| Resistance Level | $3.70 | $2.24 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 35.58 | 15.42 |
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.